Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 459 across all filing types
Latest filing 2025-08-18 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2025
Share Issue/Capital Change Classification · 85% confidence The document is a standardized monthly listing return (Form FF301) submitted to the Hong Kong Exchange detailing movements in authorised share capital, issued shares, treasury shares, share options, warrants, convertibles, other share arrangements and share repurchases for the month ended 30 April 2025. It is not an earnings release or annual report but a regulatory filing specifically concerning share capital changes and movements. This fits the Share Issue/Capital Change category (SHA).
2025-08-18 English
Next Day Disclosure Return (Resubmission)
Transaction in Own Shares Classification · 95% confidence The document is a ‘Next Day Disclosure Return’ under Hong Kong Stock Exchange Listing Rules detailing changes in issued shares, treasury shares, share repurchases on the Exchange, and confirmations by the issuer. It is a direct regulatory report of transactions in the company’s own shares (buybacks and treasury sales), not an announcement of a separate report. This corresponds to the category “Transaction in Own Shares.”
2025-08-18 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2025
Regulatory Filings Classification · 85% confidence The document is a mandatory monthly return filed with HKEX under Chapter 19B (Form FF301) showing movements in authorised share capital, issued shares, treasury shares, options, warrants, convertibles, etc. It is a routine regulatory compliance filing rather than a standalone capital raising announcement or detailed financing update. It does not fit into specific categories like earnings, delisting or AGM materials, but is a general regulatory report under listing rules. Therefore it falls into the fallback “Regulatory Filings” category (Code: RNS).
2025-08-18 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2025
Regulatory Filings Classification · 89% confidence The document is a statutory “Monthly Return for Equity Issuer” filed under HKEX Listing Rules Chapter 19B, detailing share capital movements (authorised share capital, issued shares, treasury shares, options, warrants, repurchases) for the month. It is neither an annual/quarterly financial report, earnings release, nor a one-off capital raise announcement; rather it is a recurring regulatory filing. This does not fit any of the specific categories (10-K, IR, ER, SHA, POS, etc.) but is a general compliance submission. Therefore, it falls under the fallback “Regulatory Filings” category (RNS).
2025-08-18 English
Next Day Disclosure Return (Resubmission)
Transaction in Own Shares Classification · 92% confidence The document is a Next Day Disclosure Return filed under the Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A/GEM Rule 17.27A and Main Board Rule 10.06/GEM Rule 13.13) detailing changes in issued shares, share repurchases, and treasury share transactions. It provides granular data on share buybacks, repurchase prices, and on-market sales of treasury shares, which corresponds to a company’s transactions in its own shares. Therefore, this is classified as a Transaction in Own Shares (POS).
2025-08-18 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 75% confidence The document is a brief notice from Ocumension Therapeutics (Stock Code: 1477) announcing the date of an upcoming board meeting to consider and approve its interim results and potential interim dividend. It does not include the actual interim results, nor does it announce any changes in board composition or management. It is not an AGM notice, dividend amount notice, or any other specific category. Therefore, it falls under the catch-all regulatory announcement category (Regulatory Filings – RNS).
2025-08-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.